Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial:is dose tapering practical in good responders?

Article English OPEN
Ibrahim, F.; Lorente-Cánovas, B.; Doré, C. J.; Bosworth, A.; Ma, M. H.; Galloway, J. B.; Cope, A. P.; Pande, I.; Walker, D.; Scott, D. L.;
(2017)
  • Publisher: Oxford University Press
  • Journal: volume 56,issue 11,pages2,004-2,014issn: 1462-0324, eissn: 1462-0332
  • Publisher copyright policies & self-archiving
  • Related identifiers: pmc: PMC5722050, doi: 10.1093/rheumatology/kex315
  • Subject: Clinical Science | flare | /dk/atira/pure/subjectarea/asjc/2700/2736 | biologics | RA, TNF, biologics, flare, interruption treatment, tapering | interruption treatment | Rheumatology | tapering | TNF | /dk/atira/pure/subjectarea/asjc/2700/2745 | Pharmacology (medical) | RA

<p>Objectives: RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical ... View more
  • References (42)
    42 references, page 1 of 5

    1 de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. Joint Bone Spine 2017;84:133 40.

    2 Hazlewood GS, Barnabe C, Tomlinson G et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network metaanalysis. BMJ 2016;353:i1777.

    3 Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 2012;6:429 64.

    4 Galvao TF, Zimmermann IR, da Mota LM, Silva MT, Pereira MG. Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2016;35:1659 68.

    5 Kuijper TM, Lamers-Karnebeek FBG, Jacobs JWG, Hazes JMW, Luime JJ. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol 2015;42:2012 22.

    6 Navarro-Millan I, Sattui SE, Curtis JR. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Ther 2013;35:1850 61.e1.

    7 van Herwaarden N, den Broeder AA, Jacobs W et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014;(9):CD010455.

    8 Chatzidionysiou K, Turesson C, Teleman A et al. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open 2016;2:e000133.

    9 Fautrel B, Pham T, Alfaiate T et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre noninferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Ann Rheum Dis 2016;75:59 67.

    10 Haschka J, Englbrecht M, Hueber AJ et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis 2016;75:45 51.

  • Related Organizations (10)
  • Metrics
Share - Bookmark